Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in Rat sepsis syndrome induced by cecal puncture and ligation

Authors: Chia-Lo Chang, Steve Leu, Hsin-Ching Sung, Yen-Yi Zhen, Chung-Lung Cho, Angela Chen, Tzu-Hsien Tsai, Sheng-Ying Chung, Han-Tan Chai, Cheuk-Kwan Sun, Chia-Hung Yen, Hon-Kan Yip

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

We tested whether apoptotic adipose-derived mesenchymal stem cells (A-ADMSCs) were superior to healthy (H)-ADMSCs at attenuating organ damage and mortality in sepsis syndrome following cecal ligation and puncture (CLP).

Methods

Adult male rats were categorized into group 1 (sham control), group 2 (CLP), group 3 [CLP + H-ADMSC administered 0.5, 6, and 18 h after CLP], group 4 [CLP + A-ADMSC administered as per group 3].

Results

Circulating peak TNF-α level, at 6 h, was highest in groups 2 and 3, and higher in group 4 than group 1 (p < 0.0001). Immune reactivity (indicated by circulating and splenic helper-, cytoxic-, and regulatory-T cells) at 24 and 72 h exhibited the same pattern as TNF-α amongst the groups (all p < 0.0001). The mononuclear-cell early and late apoptosis level and organ damage parameters of liver (AST, ALT), kidney (creatinine) and lung (arterial oxygen saturation) also displayed a similar pattern to TNF-α levels (all p < 0.001). Protein levels of inflammatory (TNF-α, MMP-9, NF-κB, ICAM-1), oxidative (oxidized protein) and apoptotic (Bax, caspase-3, PARP) biomarkers were higher in groups 2 and 3 than group 1, whereas anti-apoptotic (Bcl-2) biomarker was lower in groups 2 and 3 than in group 1 but anti-oxidant (GR, GPx, HO-1, NQO-1) showed an opposite way of Bcl-2; these patterns were reversed for group 4 (all p < 0.001). Mortality was highest in group 3 and higher in group 2 than group 4 than group 1 (all p < 0.001).

Conclusions

A-ADMSC therapy protected major organs from damage and improved prognosis in rats with sepsis syndrome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed
2.
go back to reference Brun-Buisson C, Meshaka P, Pinton P, Vallet B: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004, 30: 580-588.CrossRefPubMed Brun-Buisson C, Meshaka P, Pinton P, Vallet B: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004, 30: 580-588.CrossRefPubMed
3.
go back to reference Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I: The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med. 2003, 29: 1464-1471. 10.1007/s00134-003-1877-x.CrossRefPubMed Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I: The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med. 2003, 29: 1464-1471. 10.1007/s00134-003-1877-x.CrossRefPubMed
4.
go back to reference Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Eng J Med. 2003, 348: 138-150. 10.1056/NEJMra021333.CrossRef Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Eng J Med. 2003, 348: 138-150. 10.1056/NEJMra021333.CrossRef
5.
go back to reference Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M, Ayala A: Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008, 83: 523-535.CrossRefPubMed Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M, Ayala A: Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008, 83: 523-535.CrossRefPubMed
6.
go back to reference Taylor AL, Llewelyn MJ: Superantigen-induced proliferation of human CD4 + CD25- T cells is followed by a switch to a functional regulatory phenotype. J Immunol. 2010, 185: 6591-6598. 10.4049/jimmunol.1002416.CrossRefPubMed Taylor AL, Llewelyn MJ: Superantigen-induced proliferation of human CD4 + CD25- T cells is followed by a switch to a functional regulatory phenotype. J Immunol. 2010, 185: 6591-6598. 10.4049/jimmunol.1002416.CrossRefPubMed
7.
go back to reference Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, Gibot S: The relationship between CD4 + CD25 + CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care. 2010, 14: R19-10.1186/cc8876.CrossRefPubMedPubMedCentral Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, Gibot S: The relationship between CD4 + CD25 + CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care. 2010, 14: R19-10.1186/cc8876.CrossRefPubMedPubMedCentral
8.
go back to reference Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe J, Lepape A, Ayala A, Monneret G: Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009, 35: 678-686. 10.1007/s00134-008-1337-8.CrossRefPubMedPubMedCentral Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe J, Lepape A, Ayala A, Monneret G: Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009, 35: 678-686. 10.1007/s00134-008-1337-8.CrossRefPubMedPubMedCentral
9.
go back to reference Hartemink KJ, Groeneveld AB: The hemodynamics of human septic shock relate to circulating innate immunity factors. Immunol Invest. 2010, 39: 849-862. 10.3109/08820139.2010.502949.CrossRefPubMed Hartemink KJ, Groeneveld AB: The hemodynamics of human septic shock relate to circulating innate immunity factors. Immunol Invest. 2010, 39: 849-862. 10.3109/08820139.2010.502949.CrossRefPubMed
10.
go back to reference Monserrat J, de Pablo R, Reyes E, Diaz D, Barcenilla H, Zapata MR, De la Hera A, Prieto A, Alvarez-Mon M: Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care. 2009, 13: R26-10.1186/cc7731.CrossRefPubMedPubMedCentral Monserrat J, de Pablo R, Reyes E, Diaz D, Barcenilla H, Zapata MR, De la Hera A, Prieto A, Alvarez-Mon M: Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care. 2009, 13: R26-10.1186/cc7731.CrossRefPubMedPubMedCentral
11.
go back to reference Maury E, Blanchard HS, Chauvin P, Guglielminotti J, Alzieu M, Guidet B, Offenstadt G: Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care. 2003, 18: 115-120. 10.1053/jcrc.2003.50004.CrossRefPubMed Maury E, Blanchard HS, Chauvin P, Guglielminotti J, Alzieu M, Guidet B, Offenstadt G: Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care. 2003, 18: 115-120. 10.1053/jcrc.2003.50004.CrossRefPubMed
12.
go back to reference Fry DE: Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012, 78: 1-8.PubMed Fry DE: Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012, 78: 1-8.PubMed
13.
go back to reference Soares MO, Welton NJ, Harrison DA, Peura P, Shanka-Hari M, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM: An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012, 16: 1-186.CrossRefPubMedCentral Soares MO, Welton NJ, Harrison DA, Peura P, Shanka-Hari M, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM: An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012, 16: 1-186.CrossRefPubMedCentral
14.
go back to reference Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003, 57: 11-20. 10.1046/j.1365-3083.2003.01176.x.CrossRefPubMed Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003, 57: 11-20. 10.1046/j.1365-3083.2003.01176.x.CrossRefPubMed
15.
go back to reference Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD: The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol. 2005, 46: 1799-1802. 10.1016/j.jacc.2005.07.053.CrossRefPubMed Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD: The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol. 2005, 46: 1799-1802. 10.1016/j.jacc.2005.07.053.CrossRefPubMed
16.
go back to reference Weil BR, Herrmann JL, Abarbanell AM, Manukyan MC, Poynter JA, Meldrum DR: Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock. 2011, 36: 235-241. 10.1097/SHK.0b013e318225f6ae.CrossRefPubMed Weil BR, Herrmann JL, Abarbanell AM, Manukyan MC, Poynter JA, Meldrum DR: Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock. 2011, 36: 235-241. 10.1097/SHK.0b013e318225f6ae.CrossRefPubMed
17.
go back to reference Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA: Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012, 302: L1003-L1013. 10.1152/ajplung.00180.2011.CrossRefPubMedPubMedCentral Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA: Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012, 302: L1003-L1013. 10.1152/ajplung.00180.2011.CrossRefPubMedPubMedCentral
18.
go back to reference Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010, 182: 1047-1057. 10.1164/rccm.201001-0010OC.CrossRefPubMed Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010, 182: 1047-1057. 10.1164/rccm.201001-0010OC.CrossRefPubMed
19.
go back to reference De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F: Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012, 12: 574-591.CrossRefPubMed De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F: Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012, 12: 574-591.CrossRefPubMed
20.
go back to reference Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, Tivchev P, Altunkova I, Kyurkchiev DS: Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009, 126: 37-42. 10.1016/j.imlet.2009.07.010.CrossRefPubMed Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, Tivchev P, Altunkova I, Kyurkchiev DS: Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009, 126: 37-42. 10.1016/j.imlet.2009.07.010.CrossRefPubMed
21.
go back to reference Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, Chua S, Fu M, Ko SF, Leu S, Yip HK: Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med. 2011, 9: 118-10.1186/1479-5876-9-118.CrossRefPubMedPubMedCentral Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, Chua S, Fu M, Ko SF, Leu S, Yip HK: Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med. 2011, 9: 118-10.1186/1479-5876-9-118.CrossRefPubMedPubMedCentral
22.
go back to reference Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M: Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009, 58: 929-939. 10.1136/gut.2008.168534.CrossRefPubMed Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M: Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009, 58: 929-939. 10.1136/gut.2008.168534.CrossRefPubMed
23.
go back to reference Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, Chang HW, Leu S, Zhen YY, Tsai CY: Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J Pineal Res. 2012, 10.1111/jpi.12020. Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, Chang HW, Leu S, Zhen YY, Tsai CY: Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J Pineal Res. 2012, 10.1111/jpi.12020.
24.
25.
go back to reference Zhu W, Chen J, Cong X, Hu S, Chen X: Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells. 2006, 24: 416-425. 10.1634/stemcells.2005-0121.CrossRefPubMed Zhu W, Chen J, Cong X, Hu S, Chen X: Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells. 2006, 24: 416-425. 10.1634/stemcells.2005-0121.CrossRefPubMed
26.
go back to reference Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001, 107: 1395-1402. 10.1172/JCI12150.CrossRefPubMedPubMedCentral Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001, 107: 1395-1402. 10.1172/JCI12150.CrossRefPubMedPubMedCentral
27.
go back to reference Sun CK, Chang LT, Sheu JJ, Chiang CH, Lee FY, Wu CJ, Chua S, Fu M, Yip HK: Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009, 37: 1197-1205. 10.1097/CCM.0b013e31819c0667.CrossRefPubMed Sun CK, Chang LT, Sheu JJ, Chiang CH, Lee FY, Wu CJ, Chua S, Fu M, Yip HK: Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009, 37: 1197-1205. 10.1097/CCM.0b013e31819c0667.CrossRefPubMed
28.
go back to reference Yagi H, Soto-Gutierrez A, Kitagawa Y, Tilles AW, Tompkins RG, Yarmush ML: Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant. 2010, 19: 823-830. 10.3727/096368910X508942.CrossRefPubMedPubMedCentral Yagi H, Soto-Gutierrez A, Kitagawa Y, Tilles AW, Tompkins RG, Yarmush ML: Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant. 2010, 19: 823-830. 10.3727/096368910X508942.CrossRefPubMedPubMedCentral
29.
go back to reference Geng YJ: Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann N Y Acad Sci. 2003, 1010: 687-697. 10.1196/annals.1299.126.CrossRefPubMed Geng YJ: Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann N Y Acad Sci. 2003, 1010: 687-697. 10.1196/annals.1299.126.CrossRefPubMed
Metadata
Title
Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in Rat sepsis syndrome induced by cecal puncture and ligation
Authors
Chia-Lo Chang
Steve Leu
Hsin-Ching Sung
Yen-Yi Zhen
Chung-Lung Cho
Angela Chen
Tzu-Hsien Tsai
Sheng-Ying Chung
Han-Tan Chai
Cheuk-Kwan Sun
Chia-Hung Yen
Hon-Kan Yip
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-244

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.